Mapping a role for SNPs in drug development
- 1 March 2001
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 19 (3) , 209-211
- https://doi.org/10.1038/85631
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A map of human genome sequence variation containing 1.42 million single nucleotide polymorphismsNature, 2001
- Initial sequencing and analysis of the human genomeNature, 2001
- Complex promoter and coding region β 2 -adrenergic receptor haplotypes alter receptor expression and predict in vivo responsivenessProceedings of the National Academy of Sciences, 2000
- Effect of Mibefradil, a T-Type Calcium Channel Blocker, on Morbidity and Mortality in Moderate to Severe Congestive Heart FailureCirculation, 2000
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.Pharmaceutical Research, 1999
- DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase geneNature Genetics, 1998
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998
- Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CDClinical Therapeutics, 1997
- Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine IntoleranceAnnals of Internal Medicine, 1997